 VolitionRx NYSE-A:VNRX Limited said it has appointed Diagnostic Oncology CRO, LLC DXOCRO to undertake development and clinical validation studies for its Nu.Q product portfolio in the US. The diagnostics and monitoring company said DXOCRO will conduct large-scale finding studies across multiple sites in the US using Volitions Nu.Q NETs and Nu.Q Cancer tests to determine clinical utility in sepsis and cancer. 